Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study

The oncologist

article

Inbar Raber¹  Mary Linton Peters²  Aarti Asnani³  Sarah Warack⁴  Jaya Kanduri¹  Abby Pribish¹  Anuradha Godishala³  Arielle Abovich³  Anna Orbite⁴  Sujithraj Dommaraju³  Morgan Frazer⁴ 

[1] Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School;Division of Medical Oncology, Harvard Medical School, Beth Israel Deaconess Medical Center;Department of Cardiovascular Institute, Beth Israel Deaconess Medical Center, Harvard Medical School;Department of Pharmacy, Beth Israel Deaconess Medical Center, Harvard Medical School

关键词: Fluorouracil;    Capecitabine;    Cardiotoxicity;   

DOI  :  10.1634/theoncologist.2019-0762

学科分类：地质学

来源: AlphaMed Press Incorporated

【 摘 要 】

Background The fluoropyrimidines, 5-fluorouracil (5-FU) and capecitabine, are commonly used chemotherapeutic agents that have been associated with coronary vasospasm. Methods In this retrospective case-control study, we identified patients at our institution who received 5-FU or capecitabine in 2018. We compared characteristics of patients who experienced cardiotoxicity with controls. We described phenotypes and outcomes of cardiotoxic cases. Results We identified 177 patients who received fluoropyrimidines. After adjudication, 4.5% of the cohort met the criteria for cardiovascular toxicity. Coronary artery disease was more common among cases than controls (38% vs. 7%, p < .05). There was also a trend toward increased prevalence of cardiovascular risk factors in cases compared with controls. Most cardiotoxic cases had chest pain, although a minority of cases presented with nonischemic cardiomyopathy. Conclusion Cardiotoxicity phenotypes associated with fluoropyrimidine use are not limited to coronary vasospasm. Cardiac risk factors and ischemic heart disease were highly prevalent among patients with cardiotoxicity.

【 授权许可】

CC BY|CC BY-NC